OncoMatch/Clinical Trials/NCT04920149
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Is NCT04920149 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mesalamine for lynch syndrome.
Treatment: Mesalamine — Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MLH1 pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Required: MSH2 pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Required: EPCAM pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Required: MSH6 pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Excluded: PMS2 pathogenic mutation
Carriers of germline mutations in PMS2
Disease stage
Excluded: Stage III, IV
Lab requirements
Kidney function
Renal insufficiency (GFR <30ml/min/1.73m2)
Liver function
Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
Renal insufficiency (GFR <30ml/min/1.73m2); Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify